Importantly, such activation was validated in vivo, when comparing KRASG12D/+ pancreatic cancer cells to KRASLSL/+ epithelial cells in murine KRAS PanIN and PDA. The gene discussed is KRAS; the disease is Patent ductus arteriosus.